Evaluation of reporting quality of randomized controlled trials in patients with COVID-19 using the CONSORT statement
PLoS ONE2021Vol. 16(9), pp. e0257093–e0257093
Citations Over TimeTop 10% of 2021 papers
Abstract
Although many RCTs of COVID-19 have been published in different journals, the overall reporting quality of these articles was suboptimal, it can not provide valid evidence for clinical decision-making and systematic reviews. Therefore, more journals should endorse the CONSORT statement, authors should strictly follow the relevant provisions of the CONSORT guideline when reporting articles. Future RCTs should particularly focus on improvement of detailed reporting in allocation concealment, blinding and estimation of sample size.
Related Papers
- → The impact of the CONSORT statement on reporting of randomized clinical trials in psychiatry(2008)61 cited
- → Endorsement of the CONSORT guidelines, trial registration, and the quality of reporting randomised controlled trials in leading nursing journals: A cross-sectional analysis(2014)34 cited
- → Compliance of published randomized controlled trials on the effect of physical activity on primary dysmenorrhea with the consortium's integrated report on clinical trials statement: A critical appraisal of the literature(2020)7 cited
- Assessment of Reporting Quality of Randomized Controlled Trials in Seven Journals Using the CONSORT Statement(2010)
- → P09.58 Quality of randomized controlled trials reporting in the treatment of adult high grade gliomas(2017)